SecBot SecBot

CHRS

Coherus Oncology, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001512762 Biotech & Drug Discovery
$0.5060 −0.02 (−3.80%)
Nov 16 4:00 PM ET · prev $0.5260
Market cap
$83.2M
Micro cap
Consensus
Buy
83% Buy or better · 12 analysts
Median target
$7.50
+1382% · range $4.00–10.00
1 year
−55.2%
from $1.13 · Nov 17
30 days
−47.2%
from $0.9590
52-week range
$0.5060–2.51
at the low
Avg volume 20D
2.44M
Oct 29 spike 6.13M
Short interest
12.71M
≈8.2% of shares · +2.1%
Days to cover
8.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 8 added (0 new), 16 trimmed or exited.

  • AnalystsBULLISH

    10 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.225 → −$0.210 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +2.1% to 12.71M shares. 8.2 days to cover, ≈8.2% of shares.

  • TrendDOWNTREND

    51% below its 50-day average. New closing low $0.5060 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGADD1,028,832$1.2M
RENAISSANCE TECHNOLOGIES LLCADD941,828$1.1M
CITIGROUP INCDOUBLED154,112$186.5K
STRS OHIONEAR_EXIT68,200$82.5K
BNP PARIBAS FINANCIAL MARKETSADD37,754$45.7K
IEQ CAPITAL, LLCNEAR_EXIT25,541$30.9K
Cerity Partners LLCTRIM19,262$23.3K
WEALTH ENHANCEMENT ADVISORY SERVICES, LLCTRIM19,322$20.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 83% rate it Buy or better
Strong Buy4Buy6Hold2Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +1382%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 7, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 5, 2026
Newton Charles W.
Director
Jun 5, 2026
AWARD30,000 sh
Jun 5, 2026
Newton Charles W.
Director
Jun 5, 2026
AWARD60,000 sh
Jun 5, 2026
Wahlstrom Mats
Director
Jun 5, 2026
AWARD60,000 sh
Jun 5, 2026
Wahlstrom Mats
Director
Jun 5, 2026
AWARD30,000 sh
Jun 5, 2026
O'Donnell-Tormey Jill
Director
Jun 5, 2026
AWARD30,000 sh
Jun 5, 2026
O'Donnell-Tormey Jill
Director
Jun 5, 2026
AWARD60,000 sh
Jun 5, 2026
Ryan Michael Lee
Director
Jun 5, 2026
AWARD30,000 sh
Jun 5, 2026
Ryan Michael Lee
Director
Jun 5, 2026
AWARD60,000 sh

Earnings setup

Estimates
−$0.21
EPS estimate, this quarter
+7%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.21–-$0.21+0.0%$15.9M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
12,712,857
shares short
+2.1%
vs prior settlement
8.2
days to cover
≈8.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 9, 2026 SEC
Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a non-GAAP net loss of $(0.20) per share, beating the…
PRESS-RELEASE · Impact 5/10
Nov 9, 2026 Earnings
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for eso
Oct 29, 2026 SEC
Coherus Oncology announced interim clinical data from the TREGCHECK program for tagmokitug, an investigational CCR8…
8-K · Impact 6/10
Oct 14, 2026 Press
Coherus Oncology announced it will release interim clinical data for tagmokitug (anti-CCR8 antibody) combined with…
Impact 4/10
Sep 30, 2026 Inst.
UBS Group AG · ADD
1,028,832 shares ($1.2M)
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · ADD
941,828 shares ($1.1M)
Aug 17, 2026 Press
Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its…
Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

11 filings · 4 press releases · 2 bullish · 2 bearish · 1 mixed · 6 neutral
All CHRS filing & press-release reports (15)